Literature DB >> 18289041

p53 Family isoforms.

Jean-Christophe Bourdon1.   

Abstract

p63, p73 and p53 are transcription factors members of the p53 gene family involved in development, differentiation and cell response to stress. p53 gene is mutated in 50% of human cancer. Moreover, when p53 gene is not mutated then its tumour suppressor pathway is lost through interaction with abnormally expressed cellular protein or viral protein. Therefore p53 pathway inactivation is a common denominator to cancer. However, it is still difficult to associate in the clinic p53 status to cancer prognosis and diagnosis. Recent publications may have a profound impact on our understanding of p53 tumour suppressor activity. p63, p73 and p53 genes have a dual gene structure conserved in drosophila, zebrafish and man. They encode for multiple p63, p73 or p53 proteins containing different protein domains (isoforms) due to multiple splicing, alternative promoter and alternative initiation of translation. The interplay between p53, p63 and p73 isoforms are likely to be fundamental to our understanding of tumour formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18289041      PMCID: PMC3523268          DOI: 10.2174/138920107783018444

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  20 in total

1.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

4.  A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.

Authors:  Nina Anensen; Anne Margrete Oyan; Jean-Christophe Bourdon; Karl Henning Kalland; Oystein Bruserud; Bjorn Tore Gjertsen
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

5.  p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.

Authors:  Yili Yin; C W Stephen; M Gloria Luciani; Robin Fåhraeus
Journal:  Nat Cell Biol       Date:  2002-06       Impact factor: 28.824

6.  The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63.

Authors:  E Scott Helton; Jianhui Zhu; Xinbin Chen
Journal:  J Biol Chem       Date:  2005-11-30       Impact factor: 5.157

Review 7.  Decision making by p53: life, death and cancer.

Authors:  M Oren
Journal:  Cell Death Differ       Date:  2003-04       Impact factor: 15.828

8.  Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.

Authors:  V T Chow; H H Quek; E P Tock
Journal:  Cancer Lett       Date:  1993-09-30       Impact factor: 8.679

9.  Regulation of human p53 activity and cell localization by alternative splicing.

Authors:  Anirban Ghosh; Deborah Stewart; Greg Matlashewski
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  20 in total

1.  Silencing or not silencing p63 in cardiac fibroblast, risks and benefits.

Authors:  Guillermo Díaz-Araya; Jenaro Antonio Espitia-Corredor
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Drosophila p53 integrates the antagonism between autophagy and apoptosis in response to stress.

Authors:  Marion Robin; Abdul Raouf Issa; Cristiana C Santos; Francesco Napoletano; Céline Petitgas; Gilles Chatelain; Mathilde Ruby; Ludivine Walter; Serge Birman; Pedro M Domingos; Brian R Calvi; Bertrand Mollereau
Journal:  Autophagy       Date:  2018-12-28       Impact factor: 16.016

3.  Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma.

Authors:  Zhi-xiang Yang; Dong Wang; Ge Wang; Qin-hong Zhang; Jing-mao Liu; Po Peng; Xiao-hui Liu
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-31       Impact factor: 4.553

Review 4.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

5.  Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma.

Authors:  Weipei Zhu; Xiaohong Pan; Zhujuan Yang; Pengfei Xing; Yongshen Zhang; Feng Li; Xueguan Lu
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

Review 6.  Regulation of tumor suppressor p53 at the RNA level.

Authors:  Anna Vilborg; Margareta T Wilhelm; Klas G Wiman
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

7.  p53-mediated delayed NF-κB activity enhances etoposide-induced cell death in medulloblastoma.

Authors:  D Meley; D G Spiller; M R H White; H McDowell; B Pizer; V Sée
Journal:  Cell Death Dis       Date:  2010-05-13       Impact factor: 8.469

Review 8.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 9.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 10.  P63 (CKAP4) as an SP-A receptor: implications for surfactant turnover.

Authors:  Sandra R Bates
Journal:  Cell Physiol Biochem       Date:  2009-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.